StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

Research analysts at StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued on Thursday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of NASDAQ:ADXS opened at $0.03 on Thursday. The stock’s 50-day simple moving average is $0.04 and its two-hundred day simple moving average is $0.09. The stock has a market capitalization of $1.15 million, a price-to-earnings ratio of 0.00 and a beta of 1.70. Ayala Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $1.49.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.